Jasper Therapeutics, Inc. (NASDAQ:JSPR) Stock Has Consensus Price Target of $7.33

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have earned an average recommendation of “Hold” from the eight ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $7.33.

JSPR has been the topic of a number of recent analyst reports. Wall Street Zen lowered shares of Jasper Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, September 19th. William Blair assumed coverage on shares of Jasper Therapeutics in a research note on Wednesday. They issued an “outperform” rating for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Friday, July 17th. Piper Sandler started coverage on shares of Jasper Therapeutics in a report on Wednesday, August 12th. They set an “overweight” rating and a $2.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating on shares of Jasper Therapeutics in a research note on Tuesday, August 18th.

Jasper Therapeutics Stock Performance

JSPR opened at $0.53 on Tuesday. The business has a 50 day moving average price of $0.66 and a 200 day moving average price of $0.69. Jasper Therapeutics has a twelve month low of $0.32 and a twelve month high of $2.69. The firm has a market cap of $17.71 million, a P/E ratio of -0.33 and a beta of 3.16.

Jasper Therapeutics (NASDAQ:JSPR) last announced its earnings results on Friday, August 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.17. As a group, analysts anticipate that Jasper Therapeutics will post -1.14 earnings per share for the current fiscal year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for diseases involving the hematopoietic system, including conditions that require the replacement or modification of blood-forming stem cells. The company’s approach is designed to address biological barriers that can limit stem-cell transplantation, gene therapy and the treatment of mast cell–driven diseases.

Jasper’s lead product candidate is briquilimab, formerly known as JSP191, an investigational monoclonal antibody that targets CD117, a receptor found on hematopoietic stem cells and mast cells.